Given the accepted pathophysiology of PGE2-driven overproduction of VEGF, COX-2 inhibitors [non-steroid anti-inflammatory drugs (NSAIDs)], monoclonal anti-VEGF antibodies, steroids, colchicine, tamoxifen, retinoids, and risedronate to alleviate the painful polyarthritis/osteoarthropathy, as well as bisphosphonates (a potent inhibitor of osteoclastic bone resorption), are currently the treatments of choice (Zhang et al., 2013). Here, VEGFA is linked to skeletal system disorder.